TenX in-licenses Genmab's zanolimumab

Genmab A/S (CSE:GEN) granted TenX Biopharma Inc. (Philadelphia, Pa.) exclusive, worldwide rights to develop and commercialize its zanolimumab ( HuMax-CD4). The human mAb against CD4 is in a Phase III trial for cutaneous T cell lymphoma (CTCL), with data expected this year. In 2008, Genmab said it was discontinuing development of zanolimumab. Genmab will receive $4.5 million up front and is eligible for undisclosed milestones and royalties (See BioCentury Extra, Wednesday, Oct. 08, 2008). ...